• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Drug Characteristics Associated with Medication Adherence Across Eight Disease States PAWLOSKI
 

Drug Characteristics Associated with Medication Adherence Across Eight Disease States PAWLOSKI

on

  • 413 views

Chronic Illness and Multimorbidity

Chronic Illness and Multimorbidity

Statistics

Views

Total Views
413
Views on SlideShare
413
Embed Views
0

Actions

Likes
0
Downloads
6
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Drug Characteristics Associated with Medication Adherence Across Eight Disease States PAWLOSKI Drug Characteristics Associated with Medication Adherence Across Eight Disease States PAWLOSKI Presentation Transcript

    • DRUG CHARACTERISTICS ASSOCIATEDWITH MEDICATION ADHERENCEACROSS EIGHT DISEASE STATESPamala A. Pawloski, PharmD1,2; Richard J Bruzek, PharmD2; Brita Hedblom1;Steve Asche, MA1; Dana Meier, PharmD3; Cheri Rolnick, PhD, MPH11 HealthPartners Research Foundation, 2HealthPartners Pharmacy Services, 3Novartis PharmaceuticalCorporationHMORN Annual Meeting Wednesday, May 2, 2012, Seattle, WA
    • Background Medication non-adherence shown to be universally suboptimal and believed to be a key factor in achieving therapeutic goals Non-adherence represents a multifaceted challenge among patients and providers: leading to poor outcomes, compromised health and serious economic consequences Determinants of non-adherence previously described as health system, social/economic, therapy-related, condition-related, and patient-related To date, the impact of drug characteristics on medication adherence has not been studied across multiple disease states
    • Study Objective To describe medication adherence by drug characteristics across 8 different disease states:  drug class,  generic utilization,  average out-of-pocket cost/prescription To identify potential drug-specific factors by disease that may serve as targets for future intervention
    • Methods Retrospective analysis of patients with a single diagnosis and oral medication for the following conditions: •Asthma/COPD •Cancer •Depression •Diabetes •Hypercholesterolemia •Hypertension •Multiple sclerosis (MS) •Osteoporosis
    • Methods This study was conducted by HealthPartners Research Foundation  Integrated health system including 3 owned hospitals and 27 owned clinics  15 in-clinic pharmacies and a mail order pharmacy  Serve >750,000 members Included all patients > 18 years with 1 of 8 medical conditions described above
    • Methods Patient records were identified by ICD-9 DM for diagnosis and GPI code for 128 medications of interest through claims occurring between January 1, 2007 and March 31, 2009 • Diagnosis of interest must have occurred within 24 months of the most recent prescription fill • A minimum of 2 prescription medication fills for at least a 28-day supply
    • Methods Adherence was calculated by the Medication Possession Ratio (MPR) for each patient based on prescription fills within a 12-month window during the study period Binary adherence (MPR >80%) by drug characteristics within condition were tested with contingency tables and chi-square tests
    • Methods Analysis was adjusted for sex, race, age, proportion of adults with high school education, and median income Logistic regression analysis was conducted to examine predictors of adherence
    • Patient characteristics for patients with onecondition and one medication (n=14,875) Total % N=14,875 Female 60.9 Race/ethnicity White 82.8 African Am. 5.6 Asian 2.8 Hispanic 1.6 Am. Indian 0.5 Other 0.7 No answer 6.0 Age 18-49 30.4 50-59 26.2 60-69 20.7 70+ 22.7 Proportion of adults in living area with a high school education <88% 25.6 88-<93% 27.1 93-<96% 21.9 96%+ 25.5 Median=92.7% Median income of families in living area $64,500
    • Drug characteristics  within condition Asth/ Total Hyperten Depress Hyperlipid Diabetes Osteo Cancer MS COPD N=14,875 N=5,440 N=4,349 N=2,731 N=590 N=521 N=156 N=81 N=1,006 Onformulary 98.3 98.9 98.2 98.6 97.7 99.3 91.8 96.8 96.3 drug (%) On generic 75.7 91.6 74.6 66.7 22.8 85.6 78.9 41.7 0drug (%)Mean member amount paid per 30 days 0-$5 32.8 49.0 22.8 33.9 12.7 17.3 8.5 7.1 8.6 >$5-$12 39.1 38.2 46.4 38.0 16.2 52.4 31.5 27.6 8.6>$12-$22 15.2 7.9 19.1 13.8 24.4 23.2 38.2 27.6 8.6>$22-$50 11.2 4.5 10.6 12.6 39.6 6.1 18.8 31.4 45.7 >$50 1.6 0.4 1.2 1.5 7.2 1.0 3.1 6.4 28.4
    • Binary drug adherence (MPR >80%) by drug characteristics, within condition Asth/ Total Hyperten Depress Hyperlipid Diabetes Osteo Cancer MS COPD adherent adherent adherent adherent adherent adherent adherent adherent adherent N=14,875 N=5,440 N=4,349 N=2,731 N=590 N=521 N=156 N=81 N=1,007Overall (%) 69.7 77.6 62.4 78.3 32.6 59.7 76.6 90.4 84.0Generic vs.brand (%) Generic 70.9*** 77.3 60.6*** 78.8 18.8*** 59.0 79.6** 87.7 - Brand 65.9 81.1 67.6 77.3 36.6 63.5 64.5 92.3 84.0 Mean member amount paid per 30 days 0-$5 72.3*** 78.3*** 55.4*** 82.0*** 30.5 51.0*** 52.3*** - - >$5-$12 72.7 78.5 66.0 78.1 35.0 68.3 88.4 92.6 - >$12-$22 64.1 70.7 60.0 77.5 36.7 51.8 77.4 90.7 81.0 >$22-$50 61.5 77.3 66.4 71.3 30.7 42.9 67.5 88.1 85.0 >$50 50.0 50.0 56.9 66.7 26.4 - - - -* p<.05 **p<.01 ***p<.001 Pearson chi-square. N=20/row min for reporting.
    • Logistic regression: predicting adherence within condition Hyperten Depress Hyperlipid Asth/COPD Diabetes Osteo % adherent % adherent % adherent % adherent % adherent % adherent N=5,078 N=4,025 N=2,521 N=916 N=521 N=482 Brand vs. 2.82*** 1.61*** 1.56** 3.79*** 3.13** 0.67 generic (1.86-4.27) (1.34-1.94) (1.14-2.13) (2.47-5.81) (1.48-6.66) (0.37-1.21) Mean member amount paid per 30 days 0-$5 Ref Ref Ref Ref Ref Ref >$5-$12 0.92*** 1.45*** 0.61*** 1.52*** 2.01*** 5.75*** (0.79-1.06) (1.23-1.71) (0.58-0.78) 0.86-2.68 (1.19-3.41) (2.20-15.02) >$12-$22 0.53 1.04 0.46 1.02 0.95 2.10 (0.40-0.69) (0.85-1.27) (0.31-0.67) 0.61-1.7 (0.53-1.70) (0.88-5.02) >$22-$50 0.38 1.14 0.32 0.65 0.22 1.24 (0.23-0.62) (0.86-1.51) (0.21-0.49) 0.40-1.08 (0.08-0.64) (0.49-3.08) >$50 0.16 0.59 0.22 0.38 (0.06-0.42) (0.32-1.09) (0.10-0.47) 0.18-0.80 C statistic 0.65 0.61 0.69 0.67 0.70 0.74Odds ratio and 95%CI for odds ratio reported in tableAdjusted for sex, race (white/non-white), age, proportion of adults in living area with high school education, median income of families in the living area.* p<.05 **p<.01 ***p<.001 - p values are associated with entire contrast rather than individual contrasts
    • Binary drug adherence (MPR >=80%) by drugclass, within condition # adherent patients / Condition, Drug class # patients taking the Unadjusted % medication Hypertension*** Calcium channel antagonists 391/477 82.0 Angiotensin II receptor antagonists 196/242 81.0 β-blockers, α/β-blockers 1315/1659 79.3 Angiotensin converting enzyme inhibitors 777/992 78.3 Antihypertensive combinations (non-diuretic) 574/734 78.2 Antihypertensive combinations (non-diuretic) 334/444 75.2 Diuretics 574/806 71.2 Peripherally acting anti-adrenergic agents 60/86 69.8 Depression** SNRI1 359/506 71.0 Tricyclic antidepressants 118/172 68.6 SSRI2 1725-2775 62.2 Miscellaneous antidepressants 323/524 61.6 Miscellaneous antianxiety agents 33/63 52.4 Modified cyclic antidepressants 155/309 50.2
    • Binary drug adherence (MPR >=80%) by drug class, within condition # adherent patients/ Unadjusted Condition, Drug class (cont) # patients taking the % medicationHyperlipidemia*** HMG-CoA reductase inhibitors 1841/2311 79.7Combination antihyperlipidemics 106/142 74.7 Intestinal cholesterol absorption inhibitors 67/90 74.4 Fibric acid derivatives 112/165 67.9 Nicotinic acid derivatives 12/23 52.2Asthma/COPD*** Leukotriene modulators 93/140 66.4 Bronchodilators 34/52 65.4 Steroids 14/37 37.8 Adrenergics / combinations 139/431 32.3 Steroid inhalants 23/124 18.6 Nasally administered agents 25/223 11.2
    • Binary drug adherence (MPR >=80%) by drug class, within condition # adherent patients/ Unadjusted Condition, Drug class (cont) # patients taking the % medicationDiabetes Thiazolidinediones 41/56 73.2 Sulfonylureas 107/180 59.4 Biguanides 188/319 58.9 Antidiabetic combinations 8/15 53.3 GLP-1 receptor antagonists 8/20 40.0Osteoporosis** Bone density regulators 373/478 78.0 Hormone receptor modulators 15/20 75.0 Calcium 11/23 47.8Cancer* Antineoplastic hormonal agents/hormone 117/126 92.9receptor modulators Antineoplastic agents 24/30 80.0
    • Limitations Limited population to one diagnosis/medication to identify to evaluate least-confounded population Small sample size occurred in some cells (across member costs and some disease states) Generalizability may be limited due to the study population occurring within an integrated health system
    • Conclusions Variation in adherence rates by drug class underscores the need to study adherence and outcomes by both disease state and drug class Future steps include a continuous analysis of adherence to determine changes across the adherence spectrum by disease and drug class  Correlating adherence to clinical outcomes is needed to fully understand the meaning of adherence measures
    • Questions?
    • Study Population
    • MPRPatient MPR = [(Σ Days Supplied – Days Supply ofLast Fill) / (LAST Fill Date – FIRST Fill Date)] * 100 Mean MPR = (Σ Patients’ MPR / Number of patientsin the analysis) * 100